Gufic BioSciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Gufic BioSciences Ltd reported a 7.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 22.0%.
• Its expenses for the quarter were up by 3.4% QoQ and 13.8% YoY.
• The net profit increased 76.3% QoQ and increased 183.7% YoY.
• The earnings per share (EPS) of Gufic BioSciences Ltd stood at 2.18 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Gufic BioSciences Ltd is a pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse range of healthcare products. It operates primarily in the pharmaceutical industry, specializing in formulations, active pharmaceutical ingredients (APIs), and herbal products. The company is known for its focus on innovative drug delivery systems and has a significant market presence in both domestic and international markets. Recent major developments or specific product launches, if any, are not available in the provided data.

Revenue

In Q4FY26, Gufic BioSciences Ltd reported a total income of ₹250.65 crores, reflecting a quarter-over-quarter (QoQ) increase of 7.9% from ₹232.20 crores in Q3FY26 and a year-over-year (YoY) increase of 22.0% from ₹205.41 crores in Q4FY25. This rise in revenue across both periods showcases the company's ability to generate increased sales compared to the previous quarters and corresponding quarter last year. The steady growth in total income highlights the company's operational performance in terms of revenue generation.

Profitability

The company registered a profit before tax of ₹28.95 crores in Q4FY26, marking a significant QoQ increase of 63.4% from ₹17.72 crores in Q3FY26 and a YoY growth of 175.2% from ₹10.52 crores in Q4FY25. After accounting for taxes, the profit after tax stood at ₹21.90 crores, showing a QoQ rise of 76.3% from ₹12.42 crores and a YoY increase of 183.7% from ₹7.72 crores. Earnings per share (EPS) for the quarter was ₹2.18, up 75.8% QoQ from ₹1.24 and 183.1% YoY from ₹0.77. These figures indicate a substantial improvement in the company's profitability metrics over both periods.

Operating Metrics

Total expenses for Gufic BioSciences Ltd in Q4FY26 were ₹221.70 crores, increasing by 3.4% from ₹214.48 crores in Q3FY26 and by 13.8% from ₹194.89 crores in Q4FY25. Despite the rise in expenses, the company managed to achieve higher profitability, as reflected in the impressive growth of profit before tax and profit after tax. This suggests effective cost management alongside revenue growth. The tax outlay for Q4FY26 was ₹7.05 crores, increased from ₹5.30 crores in Q3FY26 and ₹2.81 crores in Q4FY25, indicating higher tax liabilities in line with higher taxable income.